Name: | Roxithromycin |
---|---|
PubChem Compound ID: | 444037 |
Description: | Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections. |
Molecular formula: | C41H76N2O15 |
Molecular weight: | 837.047 g/mol |
Synonyms: |
NINDS_000382; KBioGR_000779; DivK1c_000382; Spectrum3_001159; Spectrum4_000200; SPBio_001422; Spectrum2_001551; Spectrum_001653; KBio1_000382; KBio3_002217.
show more » |
Name: | Roxithromycin |
---|---|
Name (isomeric): | DB00778 |
Drug Type: | small molecule |
Description: | Semisynthetic derivative of erythromycin. It is concentrated by human phagocytes and is bioactive intracellularly. While the drug is active against a wide spectrum of pathogens, it is particularly effective in the treatment of respiratory and genital tract infections. |
Brand: | Rulide, Rulid, ROX, Surlid |
Category: | Anti-Bacterial Agents, Macrolides |
CAS number: | 80214-83-1 |
Indication: | Used to treat respiratory tract, urinary and soft tissue infections. |
---|---|
Pharmacology: |
Roxithromycin is a semi-synthetic macrolide antibiotic. It is very similar in composition, chemical structure and mechanism of action to erythromycin, azithromycin, or clarithromycin. Roxithromycin has the following antibacterial spectrum in vitro: Streptococcus agalactiae, Streptococcus pneumoniae (Pneumococcus), Neisseria ...
show more » |
Mechanism of Action: |
Roxithromycin prevents bacteria from growing, by interfering with their protein synthesis. Roxithromycin binds to the subunit 50S of the bacterial ribosome, and thus inhibits the translocation of peptides. Roxithromycin has similar antimicrobial spectrum as erythromycin, but is more effective against certain gram-negative bacteria, particularly ...
show more » |
Absorption: | Very rapidly absorbed and diffused into most tissues and phagocytes. |
Protein binding: | 96%, mainly to alpha1-acid glycoproteins |
Biotransformation: | Hepatic. Roxithromycin is only partially metabolised, more than half the parent compound being excreted unchanged. Three metabolites have been identified in urine and faeces: the major metabolite is descladinose roxithromycin, with N-mono and N-di-demethyl roxithromycin as minor metabolites. The respective percentage of roxithromycin and these three metabolites is similar in urine and faeces. |
Half Life: | 12 hours |
Toxicity: | Most common side-effects are gastrointestinal; diarrhoea, nausea, abdominal pain and vomiting. Less common side-effects include headaches, rashes, abnormal liver function values and alteration in senses of smell and taste. |
Affected organisms: | Enteric bacteria and other eubacteria |
Drug interaction: |
|
---|